[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidade do Sul de Santa Catarina\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":113},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100646148","phase-1-cannabidiol-oil-for-treatment-resistant-major-depression-100646148",false,"NCT07696871","Cannabidiol Oil for Treatment-Resistant Major Depression","Effects of Full-Spectrum Cannabidiol Oil on Symptoms of Treatment-Resistant Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial","ANANDA","Inclusion Criteria:\n\n* Adults aged 18 to 69 years\n* Diagnosis of Major Depressive Disorder (MDD)\n* Persistent depressive symptoms despite ongoing antidepressant treatment\n* Stable antidepressant treatment for at least four weeks before enrollment\n* Residence in Brazil\n* Ability to understand study procedures and comply with study requirements\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Current use of cannabis-derived products or cannabinoid-based medications\n* Diagnosis of bipolar disorder, schizophrenia, or other psychotic disorders\n* Current substance use disorder, except nicotine or caffeine\n* Pregnancy or breastfeeding\n* Severe or unstable medical conditions that may interfere with study participation\n* History of hypersensitivity or allergy to Cannabis sativa products or MCT oil\n* Active suicidal ideation or significant suicide risk requiring immediate intervention\n* Participation in another clinical trial within the previous 30 days\n* Inability to comply with study procedures or follow-up assessments","ALL","18 Years","69 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Major depressive disorder is one of the leading causes of disability worldwide, and a substantial proportion of patients do not achieve adequate improvement with conventional antidepressant treatments. Cannabidiol (CBD), a non-intoxicating cannabinoid derived from Cannabis sativa, has shown potential anxiolytic, anti-inflammatory, and neurobiological effects that may be relevant for depressive disorders.\n\nThe ANANDA trial is a multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy, safety, and tolerability of full-spectrum cannabidiol oil as an adjunctive treatment in adults with treatment-resistant major depressive disorder.\n\nA total of 120 participants will be randomly assigned to receive either full-spectrum cannabidiol oil or placebo for 12 weeks while maintaining stable antidepressant treatment. Clinical assessments of depressive symptoms, anxiety, sleep quality, perceived stress, and adverse effects will be performed at baseline, Week 4, and Week 12. Blood samples will be collected at baseline and after 12 weeks to investigate inflammatory and neuroendocrine biomarkers.\n\nThe primary objective is to evaluate changes in depressive symptoms after 12 weeks of treatment. Secondary objectives include the assessment of anxiety, sleep quality, perceived stress, biological markers, safety, and tolerability.\n\nThe findings of this study may contribute to the development of new therapeutic approaches for treatment-resistant depression and provide additional evidence regarding the clinical use of cannabidiol in psychiatric disorders.",[29,30],"Major Depressive Disorder (MDD)","Treatment-resistant Depression (TRD)",[32,33,34,35,36],"Cannabidiol","Cannabinoids","Major Depressive Disorder","Treatment-Resistant Depression","Mood Disorders","RECRUITING","2026-07-08",{"date":40,"type":41},"2026-07-10","ACTUAL",{"date":43,"type":41},"2026-06-01",{"date":45,"type":22},"2026-12-31",{"name":47,"class":48},"Universidade do Sul de Santa Catarina","OTHER_GOV",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":49},"100640558","phase-1-cannabigerol-oil-for-adolescents-with-adhd-can-adhd-100640558","NCT07592390","Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD)","Potential Effects of Cannabigerol in Adolescents With Attention-Deficit\u002FHyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (CAN-ADHD)","CAN-ADHD","Inclusion Criteria:\n\n* Adolescents aged 12 to 17 years\n* Diagnosis of Attention-Deficit\u002FHyperactivity Disorder (ADHD) confirmed using the SNAP-IV (Swanson, Nolan and Pelham Questionnaire, version IV)\n* History of previous treatment with pharmacological or non-pharmacological interventions without significant improvement of symptoms\n* Absence of severe psychiatric disorders or relevant physical comorbidities\n* Ability of the participant and legal guardian to understand study procedures\n* Provision of written informed consent by the legal guardian and assent by the adolescent\n\nExclusion Criteria:\n\n* Use of cannabinoid-based substances (natural or synthetic) within 30 days prior to study initiation\n* History of intolerance or adverse reactions to cannabis-derived compounds (e.g., confusion, paranoia, pruritus, excessive drowsiness, vomiting, diarrhea, or seizures)\n* Presence of any significant physical comorbidity\n* Presence of severe psychiatric disorder not related to ADHD\n* Moderate to severe cognitive impairment\n* Inability or unwillingness to complete study procedures or questionnaires adequately","12 Years","17 Years",{"count":61,"type":22},60,[25,26],"This study aims to evaluate the potential effects of full-spectrum cannabigerol (CBG) oil on cognitive and behavioral symptoms in adolescents diagnosed with Attention-Deficit\u002FHyperactivity Disorder (ADHD). ADHD is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, often associated with impairments in academic, social, and emotional functioning.\n\nThis is a randomized, double-blind, placebo-controlled clinical trial with a parallel design. A total of 60 adolescents aged 12 to 17 years, diagnosed with ADHD and with insufficient response to previous treatments, will be enrolled and randomly assigned to either the intervention group or the placebo group.\n\nParticipants in the intervention group will receive full-spectrum CBG oil (30 mg\u002FmL), administered sublingually, with individualized dosing determined by the study physician and adjusted through weekly monitoring. The placebo group will receive an inert oil matched in appearance and administration conditions.\n\nThe intervention will last for 12 weeks, including in-person clinical assessments at baseline, week 6, and week 12, as well as weekly remote monitoring to assess adherence, safety, and dose adjustments.\n\nPrimary outcomes will include changes in ADHD symptom severity measured by the SNAP-IV scale. Secondary outcomes will assess quality of life, emotional symptoms, sleep patterns, and safety profile.\n\nThis study aims to contribute to the scientific understanding of cannabinoids as a potential therapeutic option for adolescents with ADHD, a population for which current evidence remains limited.",[65],"Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[67,68,33,69],"ADHD","Cannabigerol","Adolescents","2026-05-13",{"date":72,"type":41},"2026-05-18",{"date":74,"type":22},"2026-05-01",{"date":76,"type":22},"2026-12-18",{"name":47,"class":48},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":49},"100504983","efficacy-and-safety-of-auricular-acupuncture-in-depression-during-the-covid-19-pandemic-100504983","NCT05855421","Efficacy and Safety of Auricular Acupuncture in Depression During the Covid 19 Pandemic","Efficacy and Safety of Auricular Acupuncture in Depression During the Covid 19 Pandemic: a Multicenter Triple-blinded Randomized Clinical Trial","Inclusion Criteria:\n\n* Age between 18 and 50 years old\n* PHQ-9 score between 10 and 19 (moderate depression)\n* Availability for sessions\n\nExclusion Criteria:\n\nUse complementary and integrative practices at the last 3 months; Suicidal risk evaluated by question number 9 in the PHQ-9 Severe depression score in the PHQ-9 Prior use of auricular acupuncture Pregnancy Menopause Tape and metal allergy",true,"50 Years",{"count":88,"type":22},280,[90],"NA","Participants with moderate depressive symptoms measured by PHQ-9 will be randomized to receive auricular acupuncture. The triple blinded procedure will be conducted in 12 sessions (6 weeks). The primary outcome is the response to the treatment 3 months after inclusion.",[93,94,95,96,97],"Depressive Symptoms","Depression","Anxiety","Insomnia","Quality of Life",[99,100,101,102,103,104],"depression","auricular acupuncture","clinical trial","anxiety","insomnia","quality of life","2025-01-17",{"date":107,"type":41},"2025-01-20",{"date":109,"type":41},"2023-03-01",{"date":111,"type":22},"2025-12-30",{"name":47,"class":48},""]